The IHS National Pharmacy and Therapeutics (NPTC) and the IHS National Supply Service Center (NSSC) would like to announce the addition of **Premarin® Vaginal Cream** to the IHS National Core Formulary (NCF).

**Background:**
The IHS NPTC reviewed the vaginal estrogen products at its July 2011 meeting. This review was a follow-up to the June 2010 clinical review in which a vaginal estrogen cream (any) was named to the IHS NCF. At the June 2010 meeting, NPTC provided a clinical review of the vaginal estrogen agents as a committee with direct feedback from the IHS Chief Consultant for OB-GYN. It was determined that these agents were considered clinically equivalent with no product demonstrating superiority. Because of this relative equivalence, it was felt that a pharmacoeconomic analysis could potentially allow for a named product.

The July 2011 discussion consisted primarily of a pharmacoeconomic analysis of each of the available vaginal estrogen cream products. In addition to the pharmacoeconomic data, IHS utilization data and results from a survey of IHS providers were used in the decision making process. Results from the field survey included:

- Respondents felt one agent can be stocked/used to treat a majority of patients requiring vaginal estrogen.
- Respondents favored **Premarin® Vaginal Cream** if equally available.
- Respondents favored **Premarin® Vaginal Cream** based upon availability, efficacy and tolerability.

In preparation for the July 2011 NPTC meeting, the NSSC underwent a solicitation process for sub-FSS (Federal Supply Schedule) Request for Quotes (RFQ) from IHS’ industry partners. These RFQ’s served as the official pricing structure for each product during the NPTC’s pharmacoeconomic review. This process was designed to maximize IHS’ cost avoidance potential for the selected formulary medications.

Based upon the clinical and pharmacoeconomic data presented, it was concluded to **ADD** **Premarin® Vaginal Cream** to the IHS NCF.

**Procurement Information:**
The pricing under this agreement will be available through the Pharmaceuticals Prime Vendor (PPV-McKesson). The agreement became effective August 12, 2011, however due to loading protocol; the price will not be reflected in the Prime Vendor until approximately October 1, 2011. Facilities purchasing the product between August 12, 2011 and October 1, 2011 will receive a credit and rebill for any purchases made at the FSS price.

<table>
<thead>
<tr>
<th>Product</th>
<th>Generic Name</th>
<th>NDC</th>
<th>Package Size</th>
<th>McKesson Item #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premarin®</td>
<td>Conjugated Estrogen</td>
<td>00046-0872-93</td>
<td>42.5GM</td>
<td>1158930</td>
</tr>
</tbody>
</table>

**Cost Avoidance:**
The Indian Health Care System will realize approximately $25,000 in annual cost avoidance by naming **Premarin® Vaginal Cream** to the NCF and through the subsequent NCF-based agreement.

If you have any questions regarding the content of this announcement, please contact the NPTC at nptc1@ihs.gov or the NSSC at nssc1@ihs.gov.

**Note:** Information within this document is current as of this writing and should not replace clinical judgment.